Aastrom Biosciences CEO to Present at Noble Financial Group Small Cap Conference
November 07 2005 - 4:24PM
PR Newswire (US)
ANN ARBOR, Mich., Nov. 7 /PRNewswire-FirstCall/ -- Aastrom
Biosciences, Inc. (NASDAQ:ASTM) announced today R. Douglas
Armstrong, Ph.D., Chairman and Chief Executive Officer, will
present at the Noble Financial Group Small Cap Conference. The
conference will be held November 10-11, 2005 at the Seminole Hard
Rock Hotel & Casino in Hollywood, FL. Dr. Armstrong is
scheduled to present at 3:45 p.m. (ET) on Thursday, November 10th.
A live webcast of Aastrom's presentation can be accessed by logging
onto the web and registering at
http://www.visualwebcaster.com/NobleFinancialSmallCap. An archived
replay of the presentation will also be available after the
conference for 90 days, at the same site. For more information
about the Noble Financial small Cap Conference, please contact Mark
Pinvidic at , or 1-800-688-6262. Noble Financial Group (Member
NASD, SIPC) -- now in its twenty-first year -- specializes in
small-cap equity research providing institutional investors with
detailed corporate analysis, sector and industry studies, road
shows, investment banking, market-making, and sales and trading
services. The Noble Financial Group Small Cap Conference will
feature close to fifty companies across numerous industry sectors;
including companies outside of Noble's research universe. Senior
executives will make group presentations to analysts and portfolio
managers on their business strategy and outlook and will be
available for breakout sessions and one-on-one meetings. About
Aastrom Biosciences, Inc. Aastrom Biosciences, Inc. (NASDAQ:ASTM)
is developing patient-specific products for the repair or
regeneration of human tissues, utilizing the Company's proprietary
adult stem cell technology. Aastrom's strategic position in the
tissue regeneration sector is enabled by its proprietary Tissue
Repair Cells (TRCs), a mix of bone marrow-derived adult stem and
progenitor cells manufactured in the AastromReplicell(R) System, an
industry- unique automated cell production system. TRCs are the
core component of the products Aastrom is developing for severe
bone fractures, ischemic vascular disease, jaw reconstruction and
spine fusion, with Phase I/II level clinical trials active in the
U.S. and EU for some of these indications. For more information,
visit Aastrom's website at http://www.aastrom.com/. This document
contains forward-looking statements, including without limitation,
statements concerning planned clinical trials, product development
objectives, potential advantages of TRCs, and potential product
applications, which involve certain risks and uncertainties. The
forward-looking statements are also identified through use of the
words "planned," and other words of similar meaning. Actual results
may differ significantly from the expectations contained in the
forward-looking statements. Among the factors that may result in
differences are potential patient accrual difficulties, clinical
trial results, potential product development difficulties, the
effects of competitive therapies, regulatory approval requirements,
the availability of financial and other resources and the
allocation of resources among different potential uses. These and
other significant factors are discussed in greater detail in
Aastrom's Annual Report on Form 10-K and other filings with the
Securities and Exchange Commission. CONTACTS: Kris M. Maly or
Cameron Associates Becky Anderson Kevin McGrath - Institutions
Investor Relations Department Phone: (212) 245-4577 Aastrom
Biosciences, Inc. Alyson Nikulicz - Media Phone: (734) 930-5777
Phone: (212) 554-5464 DATASOURCE: Aastrom Biosciences, Inc.
CONTACT: Kris M. Maly or Becky Anderson both of Investor Relations
Department of Aastrom Biosciences, Inc., +1-734-930-5777; or Kevin
McGrath -- Institutions, +1-212-245-4577, or Alyson Nikulicz -
Media, +1-212-554-5464 both of Cameron Associates Web site:
http://www.aastrom.com/
Copyright
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024